Photodynamic therapy with verteporfin: a new treatment in ophthalmology
- PMID: 15513441
- DOI: 10.1076/soph.16.4.201.10298
Photodynamic therapy with verteporfin: a new treatment in ophthalmology
Abstract
Photodynamic therapy (PDT) with verteporfin is a new treatment modality in ophthalmology that has previously shown its effectiveness in treatment of a variety of neoplastic pathologies. In this therapeutic approach, the photosensitizer verteporfin is activated by non-thermal laser light to obtain closure of neovascular structures. Preclinical and clinical studies have indicated that PDT is a safe, selective, and effective treatment for choroidal neovascularization in age-related macular degeneration. No significant damage to the neurosensory retina was found, which explains why PDT does not cause loss of visual acuity and may be used in a larger population than laser photocoagulation. This review summarizes the mechanisms of action of PDT, and the results of preclinical and clinical studies in ophthalmology.
Similar articles
-
Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.Surv Ophthalmol. 2000 Nov-Dec;45(3):195-214. doi: 10.1016/s0039-6257(00)00158-2. Surv Ophthalmol. 2000. PMID: 11094244 Review.
-
Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).Trans Am Ophthalmol Soc. 2008;106:357-82. Trans Am Ophthalmol Soc. 2008. PMID: 19277246 Free PMC article.
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.Arch Ophthalmol. 1999 Oct;117(10):1329-45. Arch Ophthalmol. 1999. PMID: 10532441 Clinical Trial.
-
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.Arch Ophthalmol. 2005 Apr;123(4):448-57. doi: 10.1001/archopht.123.4.448. Arch Ophthalmol. 2005. PMID: 15824216 Clinical Trial.
-
Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration.Arch Ophthalmol. 1999 Oct;117(10):1400-2. doi: 10.1001/archopht.117.10.1400. Arch Ophthalmol. 1999. PMID: 10532450 Review. No abstract available.
Cited by
-
Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ.Cancer Res. 2017 May 1;77(9):2413-2423. doi: 10.1158/0008-5472.CAN-16-3229. Epub 2017 Mar 1. Cancer Res. 2017. PMID: 28249901 Free PMC article.
-
Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.Mol Biol Cell. 2015 Nov 5;26(22):3946-53. doi: 10.1091/mbc.E15-07-0456. Epub 2015 Sep 2. Mol Biol Cell. 2015. PMID: 26337386 Free PMC article.
-
Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.Cancers (Basel). 2018 Mar 20;10(3):81. doi: 10.3390/cancers10030081. Cancers (Basel). 2018. PMID: 29558384 Free PMC article. Review.
-
Effect of molecular characteristics on cellular uptake, subcellular localization, and phototoxicity of Zn(II) N-alkylpyridylporphyrins.J Biol Chem. 2013 Dec 20;288(51):36579-88. doi: 10.1074/jbc.M113.511642. Epub 2013 Nov 8. J Biol Chem. 2013. PMID: 24214973 Free PMC article.
-
Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo.Clin Exp Med. 2022 May;22(2):221-228. doi: 10.1007/s10238-021-00738-4. Epub 2021 Jul 1. Clin Exp Med. 2022. PMID: 34196881
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical